ArticleOncoTargets and therapy2015

A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review.

Feng Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.